Orion Oyj
OMXH:ORNBV
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
32.27
49.77
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ORNBV stock under the Base Case scenario is 60.97 EUR. Compared to the current market price of 45.23 EUR, Orion Oyj is Undervalued by 26%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Orion Oyj
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ORNBV cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Orion Oyj
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Orion Oyj, a Finnish pharmaceutical and diagnostics company, has a storied history that dates back to 1917, when it was formed to meet the healthcare needs of the Finnish population. Over the decades, Orion has evolved into a key player in the European healthcare landscape, driven by its commitment to innovation and high-quality products. The company operates in two main segments: Prescription Pharmaceuticals, which includes medication for various therapeutic areas such as pain management, oncology, and neurology; and Animal Health, offering veterinary medicines and healthcare solutions. With a robust pipeline of new drugs and a focus on research and development, Orion is well-positioned to...
Orion Oyj, a Finnish pharmaceutical and diagnostics company, has a storied history that dates back to 1917, when it was formed to meet the healthcare needs of the Finnish population. Over the decades, Orion has evolved into a key player in the European healthcare landscape, driven by its commitment to innovation and high-quality products. The company operates in two main segments: Prescription Pharmaceuticals, which includes medication for various therapeutic areas such as pain management, oncology, and neurology; and Animal Health, offering veterinary medicines and healthcare solutions. With a robust pipeline of new drugs and a focus on research and development, Orion is well-positioned to address the growing global demand for effective healthcare solutions.
For investors, Orion presents a compelling narrative of stability and growth. The company has achieved consistent revenue growth and profitability, bolstered by strategic partnerships and an expansive international market presence. Orion maintains a strong balance sheet, allowing it to invest in future innovation while returning value to shareholders through dividends. The demand for its products is supported by an aging population and increasing health challenges, creating a favorable environment for sustained demand. In a rapidly changing world, Orion Oyj stands out as a resilient and adaptive company, embodying the prudent investment strategy espoused by legends like Warren Buffett and Charlie Munger.
Orion Oyj is a Finnish pharmaceutical and diagnostics company known for its diverse product offering and distinct business segments. The core business segments of Orion Oyj typically include:
-
Pharmaceuticals: This is the largest segment and focuses on the development, manufacturing, and marketing of prescription drugs. Orion emphasizes therapeutic areas such as oncology, central nervous system disorders, and pain management. The company is also involved in the development of biosimilars.
-
Consumer Health Products: This segment includes over-the-counter medications and self-care products. Orion markets a variety of consumer health products, including pain relief and cold remedies, aimed at improving everyday well-being.
-
Animal Health: Orion develops products for veterinary use, including pharmaceuticals that enhance animal health and productivity. This segment often includes a range of treatments for pets, livestock, and other animals.
-
Diagnostics: Orion also participates in the diagnostics market through the development and sale of diagnostic tests and services, particularly in the fields of medical and laboratory diagnostics.
-
Contract Manufacturing: This segment includes offering manufacturing services to other pharmaceutical companies, leveraging Orion's capabilities in production and quality assurance.
Overall, Orion Oyj is focused on innovation in drug development and maintaining a strong pipeline of products while also serving both human and veterinary health markets. The company's approach reflects a commitment to quality and sustainability, aligning with broader trends in the healthcare sector.
Orion Oyj, a Finnish pharmaceutical and biopharmaceutical company, has several unique competitive advantages that distinguish it from its rivals:
-
Strong R&D Capabilities: Orion invests significantly in research and development, which allows it to innovate and bring new products to market. The company's deep expertise in specific therapeutic areas, including oncology, central nervous system disorders, and respiratory diseases, helps it develop effective treatments.
-
Diverse Product Portfolio: Orion has a balanced mix of prescription drugs, over-the-counter products, and animal health products. This diversification reduces dependency on any single product line and spreads risk across various revenue sources.
-
Focus on Biosimilars: The company has strategically positioned itself in the biosimilars market, capitalizing on the growing demand for more affordable biologic drugs. This could provide a substantial competitive edge as patents for original biologics expire.
-
Strong Intellectual Property: Orion’s robust portfolio of patents and rights over its own formulations provides a solid foundation against competitors and allows for market exclusivity for its innovative products.
-
Solid Manufacturing Capabilities: Orion's high-quality manufacturing processes and facilities are certified globally. This quality assurance can lead to greater trust and reliability from both healthcare providers and patients.
-
Established Market Presence: With a long-standing presence in both domestic and international markets, Orion has built strong relationships with healthcare professionals, regulatory bodies, and supply chains that can be hard for new entrants to replicate.
-
Global Expansion Strategy: The company's efforts in expanding its presence in emerging markets provide it with growth opportunities that are less saturated than developed markets, giving it a competitive edge in terms of market share.
-
Commitment to Sustainability: Orion is focused on sustainability and ethical business practices, which can enhance its brand image and appeal to environmentally-conscious consumers and investors.
-
Strong Financial Position: A solid financial foundation allows Orion to invest in new technologies, acquisitions, and expansion markets, providing a buffer against economic downturns and competitive pressures.
These competitive advantages enable Orion Oyj to maintain a strong position within the pharmacological and biopharmaceutical industries, making it a formidable player against its competitors.
Orion Oyj, like any major player in the pharmaceutical and biotech sector, faces a variety of risks and challenges that could impact its operations and market position in the near future. Here are some of the key risks and challenges:
-
Regulatory Challenges: The pharmaceutical industry is heavily regulated, and changes in regulations or delays in approval processes can significantly impact Orion's ability to bring new products to market.
-
Patent Expiry: Loss of patent protection for key drugs can lead to increased competition from generics, which may impact revenues substantially.
-
Market Competition: Intense competition from both established pharmaceutical companies and new entrants in the biotech sector can challenge Orion’s market share, particularly if competitors introduce innovative products or new therapies.
-
Research and Development Risks: The process of developing new drugs is inherently risky and costly. There is always a possibility that R&D projects may fail, leading to financial losses or wasted resources.
-
Supply Chain Disruptions: Issues such as delays, shortages of raw materials, or logistical problems can disrupt production and distribution, affecting product availability and sales.
-
Economic Factors: Economic downturns or changes in healthcare funding can influence spending on pharmaceuticals. This may affect demand for Orion’s products, especially if they are not reimbursed by government health systems or insurance companies.
-
Technological Changes: Rapid advancements in medical technology and treatment methodologies could render current products obsolete, necessitating constant innovation and adaptation.
-
Global Market Risks: Orion is exposed to international markets, and geopolitical instability, trade regulations, and currency fluctuations can affect international sales and profitability.
-
Public Health Crises: Events like pandemics can alter market dynamics, potentially leading to decreased sales for certain products while increasing demand for others.
-
Reputation Risks: Issues related to product recalls, safety concerns, or negative publicity can harm the company's reputation and patient trust.
-
Investment in Digital Transformation: Adopting new technologies can be capital-intensive and complex. Failure to invest adequately in digital transformation and data analytics capabilities could disadvantage Orion in the competitive landscape.
To effectively manage these risks, Orion Oyj should focus on diversifying its product portfolio, investing in R&D, and maintaining robust quality control processes, while keeping a vigilant eye on market trends and regulatory changes.
Revenue & Expenses Breakdown
Orion Oyj
Balance Sheet Decomposition
Orion Oyj
Current Assets | 834.8m |
Cash & Short-Term Investments | 152.5m |
Receivables | 297.6m |
Other Current Assets | 384.7m |
Non-Current Assets | 622.5m |
Long-Term Investments | 300k |
PP&E | 405.1m |
Intangibles | 204.1m |
Other Non-Current Assets | 13m |
Current Liabilities | 349.4m |
Accounts Payable | 74.8m |
Other Current Liabilities | 274.6m |
Non-Current Liabilities | 345.9m |
Long-Term Debt | 234.1m |
Other Non-Current Liabilities | 111.8m |
Earnings Waterfall
Orion Oyj
Revenue
|
1.3B
EUR
|
Cost of Revenue
|
-551.1m
EUR
|
Gross Profit
|
707.9m
EUR
|
Operating Expenses
|
-413.2m
EUR
|
Operating Income
|
294.7m
EUR
|
Other Expenses
|
-62.3m
EUR
|
Net Income
|
232.4m
EUR
|
Free Cash Flow Analysis
Orion Oyj
EUR | |
Free Cash Flow | EUR |
Orion's Q1 showed strong performance with sales growing by 11% to EUR 308.5 million and operating profit increasing to EUR 56 million, a 1% uptick. Key contributors were better-than-expected Nubeqa royalties and Easyhaler sales. The company received a EUR 30 million milestone from Bayer and saw a substantial improvement in cash flow partly due to a EUR 41 million pension fund transfer. Orion reaffirms its financial goals, aiming for revenue growth beyond 8% CAGR and maintaining high equity and return ratios. CEO Liisa Hurme noted the positive impact of green initiatives on Easyhaler sales in the UK and Germany.
What is Earnings Call?
ORNBV Profitability Score
Profitability Due Diligence
Orion Oyj's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
Score
Orion Oyj's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
ORNBV Solvency Score
Solvency Due Diligence
Orion Oyj's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
Orion Oyj's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ORNBV Price Targets Summary
Orion Oyj
According to Wall Street analysts, the average 1-year price target for ORNBV is 50.27 EUR with a low forecast of 35.35 EUR and a high forecast of 66.15 EUR.
Dividends
Current shareholder yield for ORNBV is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is headquartered in Espoo, Etela-Suomen and currently employs 3,355 full-time employees. The company went IPO on 2006-07-03. The firm is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.
Officers
The intrinsic value of one ORNBV stock under the Base Case scenario is 60.97 EUR.
Compared to the current market price of 45.23 EUR, Orion Oyj is Undervalued by 26%.